Articles

Denosumab Superior to Zoledronic Acid in Delaying SREs

Denosumab delayed or prevented skeletal-related events (SREs) better than zoledronic acid, according to a study comparing the two agents in patients with breast cancer and bone metastases.

TON - Daily

The prognosis for patients with biliary tract cancer is poor, and no standard palliative care has been defined. Now Austrian researchers report that adding cetuximab to gemcitabine and oxaliplatin (GEMOX) for patients with advanced biliary tract cancer results in a high overall response rate and good disease control and is well tolerated.

TON - Daily

Age is an important factor when considering tamoxifen therapy for older women with early-stage breast cancer, according to a large retrospective study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology. The findings indicate that older women treated with conservative surgery and radiation therapy (CS + RT) derive only limited benefit from tamoxifen.

TON - Daily

Patients with chronic lymphocytic leukemia (CLL) who have insufficient levels of vitamin D at the time of diagnosis are at greater risk of cancer progression and death than patients with adequate levels, Mayo Clinic researchers have found.

Lung Cancer

TON - December 2010, Vol 3, No 8

A large National Cancer Institute (NCI)–sponsored study has shown for the first time that a screening method can reduce deaths from lung cancer by detecting cancers at relatively early stages.

TON - Daily

Use of aspirin or other anticoagulants in addition to radiation therapy or surgery may reduce the risk of dying of prostate cancer by more than half, according to a large study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology.

TON - Daily

Treatment with a combination of hormone therapy and radiation therapy (RT) improves overall and disease-specific survival in men with locally advanced prostate cancer compared with hormone therapy alone, according to interim results of a study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology.

TON - Daily

Adding chemotherapy to radiotherapy (RT) for muscle-invasive bladder cancer is well tolerated and improves loco-regional disease-free survival (LRDFS) compared with RT alone, according to a study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

TON - Daily

The US Food and Drug Administration (FDA) has approved dasatinib (Sprycel, Bristol-Myers Squibb) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

TON - Daily

A study by Virginia Commonwealth University Massey Cancer Center researchers showed that most terminally ill cancer patients who were eligible for genetic testing did not receive it even though it could potentially save a relative's life.

The research, reported by John M. Quillin, PhD, and associates in the October issue of the Journal of Genetic Counseling, is the first to document the prevalence of hereditary cancer risk and the need for genetic services and patient education among terminally ill cancer patients.

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 359 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: